Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 May 2025
President Donald Trump's choice for U.S. surgeon general has raised eyebrows for promoting the use of psychedelic drugs, such as psilocybin, in a 2024 book and her personal newsletter.
Read Full NewsA nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.
Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.
1.
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer
2.
Cancer Patients' Depression May Be Helped by Psilocybin.
3.
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
4.
Coupling dye and fiducial marking can improve precision in pulmonary nodule surgical resection
5.
Providing essential cancer care to rural communities
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
3.
Phosphate Vs. Phosphorus: What Is The Difference?
4.
Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity
5.
Case Study: Genomic Medicine in Precision Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
4.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge